Jinhua Wang, PhD
Dr. Wang received her Ph.D. in organic chemistry from Utah State University in 2006 where her project involved development of carbohydrate-based antibacterial and anti-viral agents. After post-doctoral training focusing on synthesis of glycolipids and development of anti-HIV inhibitors in The Ohio State University and University of Massachusetts Medical School, Dr. Wang joined Gray lab in 2008 and was promoted to research scientist in 2012. Dr. Wang is working on developing and optimizing small molecule inhibitors of kinases, including mTor, ALK, EphA2, ERK5, and SIK.
Dr. Wang received her Ph.D. in organic chemistry from Utah State University in 2006 where her project involved development of carbohydrate-based antibacterial and anti-viral agents. After post-doctoral training focusing on synthesis of glycolipids and development of anti-HIV inhibitors in The Ohio State University and University of Massachusetts Medical School, Dr. Wang joined Gray lab in 2008 and was promoted to research scientist in 2012. Dr. Wang is working on developing and optimizing small molecule inhibitors of kinases, including mTor, ALK, EphA2, ERK5, and SIK.